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Abstract.  We describe a novel approach to study 
tyrosine-phosphorylated (PY) integrins in cells trans- 
formed by virally encoded tyrosine kinases. We have 
synthesized a peptide (PY/~ peptide) that represents a 
portion of the cytoplasmic domain of the/~1 integrin 
subunit and is phosphorylated on the tyrosine residue 
known to be the target of oncogenic tyrosine kinases. 
Antibodies prepared against the PY/3~ peptide, after 
removal of cross-reacting antibodies by absorption and 
affinity purification, recognized the PYfll peptide and 
the tyrosine-phosphorylated form of the intact/~ 
subunit, but did not bind the nonphosphorylated/~ 
peptide, the nonphosphorylated/~ subunit or other 
unrelated tyrosine-phosphorylated proteins. The anti- 
PY/~I antibodies labeled the podosomes of Rous sar- 
coma virus-transformed fibroblasts, but did not detect- 
ably stain nontransformed fibroblasts. The localization 
of the tyrosine phosphorylated ~  subunit appeared 
distinct from that of the/~1 subunit. Adhesion plaques 
were stained by the anti-/~l subunit antibodies in Rous 
sarcoma virus-transformed fibroblasts plated on 
fibronectin, whereas neither podosomes nor adhesion 
plaques were labeled on vitronectin or on uncoated 
plates. Anti-phosphotyrosine antibodies labeled podo- 
somes, adhesion plaques and cell-cell boundaries 
regardless of the substratum. One of the SH2 domains 
of the p85 subunit of phosphatidylinositol-3-kinase 
bound to the PY~I peptide, but not to the non- 
phosphorylated ~1 cytoplasmic peptide. Other SH2 do- 
mains did not bind to the PY~1 peptide. These results 
show that the phosphorylated form of the ~  integrin 
subunit is detected in a different subcellular localiza- 
tion than the nonphosphorylated form and suggest that 
the phosphorylation on tyrosine of the ~  subunit cyto- 
plasmic domain may affect cellular signaling pathways. 
I 
NTEGRINS are a family of transmembrane proteins com- 
posed of an c~ and/3 subunit.  Many of the integrins 
are receptors for extracellular matrix proteins and medi- 
ate cell adhesion to matrices (for reviews,  see' Ruoslahti, 
1991; Hynes, 1992). The//~ integrin subunit combines with 
several c~ subunits to form receptors for extracelhlar matrix 
proteins such as fibronectin, laminin, and collagens. The cy- 
toplasmic  domains of the  integrins  are thought to  bind 
cytoskeletal and  other intraceilular components.  The  ~1 
integrin subunit has been shown to interact with talin (Hor- 
witz et al., 1986) and ce-actinin (Otey et al., 1990, 1993) in 
vitro.  Furthermore, the cytoplasmic tail is necessary and 
sufficient for ~1 integrins  to localize  in adhesion plaques 
(Solowska et al., 1989; l_aFlamme et al., 1992). Cell trans- 
formation by  vitally encoded tyrosine kinases  has  been 
shown to cause increased phosphorylation on tyrosine of the 
~1 subunit cytoplasmic domain (Hirst et al.,  1986). 
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The transforming protein of Rous sarcoma virus (RSV),I 
p60  v~'c, is a cytoplasmic tyrosine kinase with constitutive 
activity (Hunter and Sefton, 1980). Fibroblasts transformed 
by RSV express high levels of p60v-s% which causes exten- 
sive protein tyrosine phosphorylation of cellular proteins 
(Sefton et al., 1980). It is thought that the phosphorylation 
on tyrosine of critical substrates leads to the rounded mor- 
phology, disorganization  of the cytoskeleton and decreased 
adhesiveness  to  the substratum  that are characteristic of 
RSV-transformed cells. The search for substrates involved in 
the morphological alterations of RSV-transformed cells has 
led to the identification of a number of cytoskeletal compo- 
nents that are phosphorylated on tyrosine at higher levels in 
transformed fibroblasts  than in normal fibroblasts.  These 
cytoskeletal proteins include vinculin (Sefton et al., 1981), 
1. Abbreviations  used in  this paper:  DMF,  dimethylformamide; FMOC, 
9-fluorenylmethyloxycarbonyl;  PI-3-kinase,  phosphatidylinositol-3'-ki- 
nase;  PLC,  phospholipase C;  PY,  tyrosine phosphorylated; RSV, Rous 
sarcoma virus;  SH2,  src homology 2;  t-boc, t-butyloxycarbonyl;  TFA, 
trifluoracetic  acid. 
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paxillin  (Glenney and  Zokas,  1989),  tensin  (Davis et al., 
1991), and, as has been shown more recently, cadherins and 
catenins  (Matsuyoshi  et al.,  1992;  Behrens  et al.,  1993; 
Harnaguchi  et  al.,  1993).  However,  in  most  cases  these 
cytoskeletal proteins are phosphorylated on tyrosine at low 
stoichiometry in RSV-transformed ceils. 
To demonstrate that tyrosine phosphorylation of structural 
proteins leads to morphological alterations, even if it occurs 
at  low stoichiometry,  the  specific  subcellular  localization 
and binding properties of the tyrosine-phosphorylated pro- 
teins need to be examined and compared to those of the non- 
phosphorylated  proteins.  The localization  of the tyrosine- 
phosphorylated molecules in structures that are crucial to 
maintain  the cytoskeletal organization  and a  normal mor- 
phology, such as cell-substrate adhesion sites, would sup- 
port the importance of tyrosine-phosphorylation in generat- 
ing  a  transformed  phenotype.  These  experiments  are  in 
principle  straightforward,  but have been hampered  by the 
lack of antibodies  capable of recognizing  specifically the 
tyrosine-phosphorylated  forms  of proteins.  Here  we  de- 
scribe the use of a tyrosine-phosphorylated peptide (PY/30, 
corresponding to a region of the cytoplasmic domain of the 
/3~ subunit, to generate antibodies specific for the tyrosine- 
phosphorylated  /3~  integrin  subunit.  The  residue  that  is 
phosphorylated in the peptide represents a consensus site for 
tyrosine-phosphorylation  in the cytoplasmic domain of the 
/32  integrin  subunit  and,  thus,  is thought  to represent  the 
tyrosine  which  is  phosphorylated  in  RSV-transformed 
fibroblasts  (Tamkun  et  al.,  1986;  Argraves  et  al.,  1987; 
Tapley et al.,  1989; Hynes,  1990). 
We have used these anti-PY/3~ antibodies to show that the 
tyrosine-phosphorylated/3~  subunit  is concentrated  in  the 
podosomes of RSV-transformed NIH 3T3 cells, a localiza- 
tion distinct from both that of/3t integrins and phosphotyro- 
sine in general. We discuss the possible function of tyrosine 
phosphorylated/3t  integrins  in the podosomes,  which are 
round, dynamic adhesion structures also known as rosettes 
and  believed  to  be  associated  with  invasiveness  (David- 
Pfeuty and Singer,  1980; Tarone et al.,  1985; Marchisio et 
al.,  1987;  Ruoslahti and Giancotti,  1989). We also present 
evidence that  the tyrosine phosphorylated/3~  subunit may 
specifically interact with phosphatidylinositol (PI)-3-kinase. 
Materials and Methods 
Synthetic Peptides 
The tyrosine-phosphorylated peptides KWDq'GENPIY(P)KSAVTT  (PYflO 
and KWDTANNPLY(P)KEATST(PY/33),  corresponding to parts of the cy- 
toplasmic domains of the human/51 subunit (Argraves et al.,  1987) and/33 
subunit (Fitzgerald et al.,  1987) subunits, respectively, were synthesized 
manually by solid phase technique (Larsson et al.,  1993). A 9-fluorenyl- 
methyloxycarbonyl (FMOC) protocol was used in which the FMOC group 
was  deblocked  with  morpholine  (20%  in dimethylformamide  [DMF]), 
hydroxyl groups  wore protected as t-butyl ethers or esters,  the E-amino 
group in lysine as a  t-butyloxycarbonyl (t-Boo) derivative and the phos- 
phorylated tyrosine as a dibenzyl ester. The synthesis was initiated on a 
threonine t-butyl  ether  Sasrin  resin.  Coupling  of the  amino  acids  was 
achieved by means of preformed 1-hydroxybenzotriazole esters in a three- 
fold excess in DMF and the completion of the reaction was monitored by 
a  ninhydrin method (Satin et al.,  1981).  31p and 1H NMR spectra were 
measured on all phosphorylated compounds in a JEOL 270 MHz spectrom- 
eter and peptides were characterized by amino acid analysis, HPLC,  and 
gasphase microsequencing. 
After removal of the last FMOC group the side chain protected peptide 
was released from the resin by trifluoracetic acid (TFA),  1% in CH2C12, 
and was then desalted on Sephadex G15 in 0.1 M  NH4HCO3 and lyophi- 
lized.  The protected PY/3t  peptide gave a 3lp NMR signal at  -5.8 ppm. 
Attempts to remove the benzyl protecting groups through hydrogenolysis 
(Pd/C,  50 psi) reduced  the tyrosine and removed the phosphate.  It was 
found, however, that the benzyl groups could be removed concomitantly 
with the t-butyl groups by means of TFA. The protected peptide (272 nag), 
TFA (5 ml), indole (0.2 g), and p-cresol (0.2 g) were stirred at 0*C under 
nitrogen for 1 h. The peptide was then precipitated with dry ether at -60"C, 
taken up in 10% aqueous acetic acid, lyophilized, and then desalted over 
a Sephadex GI5 colunm giving the pure phosphopeptide in a yield of 33 
mg having 31p NMR signal at  -2.9 ppm.  In a sample that had not been 
fully deprotected an NMR signal corresponding to the monobertzyl deriva- 
tive of the peptide was observed at -4.2 ppm. The three positions of the 
31p NMR signal were consistent with the appearance of the benzyl signals 
in the tH NMR spectra.  The tyrosine-phosphorylated/33 subunit peptide 
(PY/33) was  synthesized essentially as peptide PY/31,  giving in all steps 
similar 31p NMR signals. After the TFA deblocking procedure followed by 
desalting 77 nag PY/33 poptide was obtained. Nonphosphorylated/31  inte- 
grin peptide KKKEKEKMNAKWDTGENPIYKSAVTTVNPKYEGK  and 
/33 integrin peptide KFEEERARAKWDTANNPLYKEATSTFTNITYRGT 
were synthesized at the Protein Chemistry Facility at the La Jolla Cancer 
Research Foundation (La Jolla, CA). 
Proteins 
Phosphotyrosine-BSA was prepared by coupling 4  nag phosphotyrosine to 
5  mg BSA using glutaraldehyde as described  (Wang,  1991).  Vitronectin 
purified from human plasma according to Yatohgo et al. (1988) was a gift 
from  Dr.  Bianca Tomasini-Johansson,  University of Uppsala  (Uppsala, 
Sweden), human plasma fibronectin was obtained from the Blood Transfu- 
sion Service of the Finnish Red Cross (Helsinki, Finland) and calf intestine 
alkaline phosphatase from Boehringer (Indianapolis, IN). 
Antibodies 
1 mg PY/3t  peptide in 300/~1 PBS with 50/~M Na3VO4 was mixed with 
12.5  /~1 of  1  mg/ml  methylated BSA (Benoit et ai.,  1982) and 300  /~1 
Freund's  complete  adjuvant  and  injected  subcutaneously  into  a  New 
Zealand white female rabbit. Incomplete adjuvant was used for booster im- 
munizations.  The antiserum was made  1 mM  NaaVO4  and precipitated 
with (NI-I4)2SO4 at 40%  saturation; the precipitation and the subsequent 
steps were performed at 4"C. The precipitate was dissolved in half of the 
originai volume of PBS with 1 mM Na3VO4,  dialyzed towards PBS-1  mM 
Na3VO4 and absorbed by passing through a column of BSA-agarose and a 
column of the nonphosphorylated/31 peptide coupled to CNBr-Sepharose 
according  to  the  manufacturer's  instructions  (10  mg peptide/ml  resin). 
Na3VO4 was added to the serum to inhibit the phosphotyrosine phospha- 
tases that may be present and would cause the dephosphorylation of the 
tyrosine phosphorylated reagents that were incubated with the serum (e.g., 
the  PY/31 on the affinity-column).  This  flowthrough  was  mixed  with a 
phosphotyrosine-rich protein aggregate suspension 00 t~l per mi of the anti- 
body solution). The phosphotyrosine proteins were prepared from a 10 ml 
culture of v-abl-expressing Escherichia coli as described (Wang, 1991). Af- 
ter incubation on a rocker overnight, this mixture was centrifuged at 10,000 
g  for 10 min. The supernatant was applied to a column of PY/31 peptide 
coupled to CNBr-Sepharose (2 rng peptide/ml resin) and antibodies were 
eluted with 0.1  M  glycine-HCl,  pH 2.5, containing 1 mM Na3VO4.  The 
eluate was neutralized with a 1/10 vol of 1 M Tris-HCI, pH 8.0. This proce- 
dure yielded ,x,900/~g affinity-purified anti-PYB~ antibodies from 40 ml 
antiserum. Affinity-purified rabbit anti-phosphotyrosine (anti-PY) antibod- 
ies (Wang, 1991) and rabbit antisera against cytoplasmic peptides of the ~v 
(Freed  et  al.,  1989)  and  /3t  (Giancotti  and  Ruoslahti,  1990)  integrin 
subunits have been described.  Anti-/31  subunit antibodies were  affinity- 
purified on a  column of the peptide coupled to Sepharose.  Mouse anti- 
p60  v-s'~ mAb was from Oncogene Science (Uniondale, NY). 
Cells 
RSV-transformed and  nontransformed mouse  NIH  31"3 fibroblasts were 
gifts from Dr.  Janice Buss,  Iowa State University, and were cultured in 
DME (GIBCO, Grand Island, NY) with 10% FCS (Tissue Culture Biologi- 
cals,  Tulare, CA) and glutamine pen-strep (Irvine Scientific, Santa Aria, 
CA). v-abl expressing E. coli (Wang, 1991) were grown in LB medium with 
50 t~g/ml ampicillin. 
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CNBr-Sepbarose  and protein A-Sepharose were from Pharmacia (Piscata- 
way, NJ), goat anti-rabbit IgG-pemxidase  conjugate from BioRad (Rich- 
mond, CA), octylglucoside from Caibiochem (La Jolla, CA), precast SDS- 
PAGE gels from Novex (San Diego, CA), diaminobenzidine  from Cappel 
and  [32p]phosphoric acid from NEN.  Other  reagents  were  from Sigma 
Chem. Co. (St. Louis, MO). Biotinylated PhosphoBloff" SH2 (src homol- 
ogy 2) domain reagents were from Oncogene Science (Uniondale, NY). The 
SH2 domains used are: the human p60  '''c SH2 domain, the bovine phos- 
pholipase C (PLC)3,-1 amino-terminal SH2 domain and the bovine carboxy- 
terminal  SH2 domain  of the p85  subunit of PI-3-kinase.  Avidin and bi- 
otinylated horseradish  peroxidase were from Clontech (Paio Alto, CA). 
ELISA 
Microtiter plate wells were coated overnight at room temperature with 100 
/~1 of 10/zg/ml peptide solutions in PBS containing 0.5% glutaraldehyde, 
pH 7.4, or with 100 #1 cell lysates as described below. After coating, wells 
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Figure  1.  Binding of anti-integrin and anti-phosphotymsine anti- 
bodies to integrin cytoplasmic domain peptides in ELISA. ELISA 
was performed with affinity-purified antibodies  against the PY/3t 
cytoplasmic peptide (A), the/9, cytoplasmic peptide (B), or phos- 
photymsine (anti-PY) (C) in micmtiter wells coated with PY/~,, 
~,  PY/33, or/53  peptides  at  10/~g/ml  or with  l0  #g/ml  phos- 
photyrosine  as  a  BSA  conjugate  (PYBSA).  Antibodies  against 
tyrosine-phosphorylated/51  (anti-PY/31)  recognize only the PY/~I 
peptide  and  not  the  nonphosphorylated  ~1  peptide  or  other 
tyrosine-phosphorylated substrates. 
were washed three times with PBS, blocked for 2 h with PBS containing 
3% BSA and 1 mM Na3VO4, washed again with PBS, then incubated with 
100 td primary antibody in PBS with 0.05 % Tween 20 and 1 mM Na3VO4 
for 4 h, washed three times with PBS-Tween, incubated with anti-rabbit 
IgG-horseradish  pcmxidas¢ conjugate  1:1,000 in PBS-Tween-Na3VO4 for 
2 h, and washed again three times with PBS-Tween and then three times 
with PBS. Finally, pemxidase  was assayed with 0.4 mg/ml ortho-phenyl- 
diarnine and 0.01% H202 in a buffer of 24.3 mM citric acid and 51.4 raM 
Na2HPO4 and the result read at 450 nm. 
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Figure 2.  Specific inhibition of the binding of anti-PY/~t antibod- 
ies by the PYflt  peptide in ELISA.  ELISA was performed with 
afffinity-purified anti-PYfll  subunit antibodies at  10/tg/ml in mi- 
crotiter wells coated with  10 #g/rnl of the PYfl~ peptide (A),  or 
anti-phosphotyrosine  antibodies  at  l  #g/ml  in  microtiter  wells 
coated  with  10  /~g/ml of the  PYfl~  peptide  (B),  or  with  anti- 
phosphotyrosine  antibodies  at  1  #g/Ira  in wells coated  with  10 
/zg/ml of phosphotyrosine as a BSA conjugate (PYBSA) (C). Buffer 
only  (control),  the  indicated  peptide  at  100  #g/ml  or  40  mM 
phenylphosphate  were added in the primary antibody solution. 
Johansson et al. Tyrosine-phosphorylated [31 lntegrin  1301 Figure  3.  Immunoprecipitation  with  anti-PY/~ 
peptide antibodies of cell-surface-iodinated inte- 
grin from  RSV-transformed  and nontransformed 
mouse  NIH  3"1"3 fibroblasts.  RSV-transformed 
(lane 1) and nontransformed (lane 2) cells were 
surface iodinated and lysed.  Lysates were immu- 
noprecipitated with and-PY~t by using 1:10 dilu- 
tion of absorbed antiserum. 
Binding Assay with SH2 Domains 
Microtiter plates were coated and blocked with peptides as described above 
for ELISA experiments.  After blocking,  wells were incubated with 100 #1 
biotinylated SH2 domain reagent (5/~g/ml in PBS, 0.05 % Tween 20 con- 
taining 1 mM Na3VO4 and 5 mM DTT) for 1 h at room temperature.  The 
wells were washed three  times with PBS-Tween, incubated with a mixture 
of avidin (1:250) and biotinylated horseradish peroxidase (1:250) in PBS- 
Tween-Na3VO4 for 30 rain, washed three times with PBS and finally devel- 
oped as above. 
usI Surface Labeling of Cells 
RSV-transformed cells were treated for 15 rain with 1 mM Na3VO4 and 2 
mM 1-1202 (Volberg et ai.,  1992) in serum-freo DME, washed twice with 
cold PBS-100/zM Na3VO4, once with PBS, and then harvested and iodi- 
nated as described (Pytela et al.,  1985), except that cells were lysed in 50 
mM octylglucoside,  1 mM CaCI2,  1 mM MgC12, 1 mM Na3VO4 TBS, pH 
7.4,  containing protease inhibitors as above. 
Immunoprecipitation 
Lysates of iodinated cells were immunoprecipitated as described (Giancotti 
and Ruoslahti,  1990),  except that 1 mM Na3VO4 was present throughout 
and immunoprecipitates were washed only with octylglucoside  buffer (and 
not in SDS). Immunoprecipitates were analyzed by SDS-PAGE in a 6% gel 
and visualized by autoradiography. 
Immunofluorescence 
Cells  were  harvested with trypsin-EDTA,  diluted  1:10 in  DME-gluta- 
mine-pen-strep-10 % FCS and added to noncoated glass coverslips or to cov- 
erslips coated for 2 h at room temperature with 10/~g/ml vitronectin or 
fibronectin in PBS. After 24 h cells were fixed for 10 rain in 3% parafor- 
maldehyde,  60 mM sucrose,  50/~M Na3VO4 in PBS, washed twice with 
PBS and permeabilized with 0.5%  NP-40,  1 mM Na3VO4, in PBS for 15 
min at room temperature.  Cells were washed again twice with PBS, once 
with PBS-3 % BSA and incubated with primary antibody in PBS-3 % BSA-1 
mM Na3VO4 for 1 h,  washed as before,  incubated with anti-rabbit IgG- 
rhodamine 1:150 in TBS-3%  BSA-1 mM Na3VO4 for 45 min and finally 
washed three times with PBS before observation. 
Phosphatase Treatment of Cells and PY~I Peptide 
Microtiter plate wells coated with peptide solutions or cells fixed and per- 
meabilized  for immunofluorescence  were treated with 100 U/ml alkaline 
phosphatase in supplied dephosphorylation buffer (Bochringer Mannheim) 
for 24 h at 37°C  and then washed with PBS and PBS-BSA and incubated 
with antibodies or SH2 domains as above. Control cells received only de- 
phosphorylation buffer containing 1 mM Na3VO4. 
Results 
Specificity and Reactivity of 
Anti-tyrosine-phosphorylated ~I lntegrin 
Subunit  Antibodies 
The crude antiserum from a  rabbit  immunized with the 
PY/~  peptide contained reactivities  to both the PY/3t pep- 
tide and the nonphosphorylated/~ cytoplasmic peptide as 
well as to phosphotyrosine.  However, absorption  of the an- 
tiserum on nonphosphorylated/3~ subunit peptide and on a 
mixture of tyrosine phosphorylated proteins,  followed by 
affinity purification on a PY/3~ peptide column, yielded an- 
tibodies  specific  for the PY/3t peptide.  In ELISA  experi- 
ments, these antibodies recognized only the tyrosine-phos- 
phorylated /3~  peptide and not the nonphosphorylated  El 
peptide or other tyrosine-phosphorylated substrates, such as 
the related PY/33 peptide or phosphotyrosine  coupled to 
BSA (Fig. 1 A). In addition,  dephosphorylation of the PY/3~ 
peptide by alkaline phosphatase greatly reduced (by about 
70%) the binding of  the antibodies (not shown). In contrast, 
conventional anti-/3~ subunit cytoplasmic peptide antibodies 
(Giancotti  and  Ruoslahti,  1990) recognized  /3,  peptides 
regardless of phosphorylation  (Fig.  1 B) and, similarly, an 
anti4t~ subunit  cytoplasmic peptide antiserum recognized 
the PY~3 peptide (not shown). As expected, anti-phospho- 
tyrosine antibodies  (Wang, 1991) recognized the tyrosine- 
phosphorylated ~  and/33 peptides as well as phosphotyro- 
sine coupled at BSA, but not the nonphosphorylated  peptides 
nor BSA (Fig.  1 C). The results with anti-phosphotyrosine 
antibodies also confirmed that the PY/3~ and PY/33 peptides 
indeed contain phosphorylated tyrosine residues and that the 
phosphotyrosine-BSA  coupling was effective. 
The specificity  of the anti-PY~,  antibodies  was further 
demonstrated by  the  inhibition  observed with  the  PY/~ 
peptide in ELISA experiments and by the lack of inhibition 
with the nonphosphorylated/3~  peptide  (Fig.  2 A).  More- 
over, phenylphosphate  only marginally  inhibited  the anti- 
PY{/~ antibodies (Fig. 2 A), whereas it inhibited the binding 
of the anti-phosphotyrosine  antibodies to phosphotyrosine- 
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Figure  4.  Binding  of  anti- 
PY/3t  antibodies to lysates of 
RSV-transformed  (sre-3T3) 
and  nontransformed  mouse 
NIH  3T3  (3T3)  fibroblasts in 
ELISA.  Cells  were  washed 
three  times  with  cold  PBS 
containing  100  /zM  Na3VO4 
lysed on the plate on ice in 50 
mM  octylglucoside,  1  mM 
CaCl2,  1 mM MgCl2,  1 mM 
Na3VO4,  1 mM PMSE  2  #g/ 
ml aprotinin, 2/zg/ml leupeptin,  1 /~g/ml pepstatin, and TBS, pH 7.4.  The two lysates were adjusted to the same protein concentration. 
ELISA was performed with affinity-purified anti-PYBt (A) or anti-/~ (B) antibodies as described in Materials and Methods. The lysates 
were coated onto microtiter wells diluted  1:50 in TBS which contained  1 mM CaC12  and  1 mM MgCI2. 
The Journal of Cell Biology, Volume 126, 1994  1302 Figure 5. Immunofluorescent  localization of the tyrosine phosphorylated/~t integrin subunit. Immunofluorescence  was performed with 
100 tzg/ml of affinity-purified  and-PY/31 antibodies, using RSV-transformed  mouse NIH 31"3 fibroblasts plated on noncoated glass. No 
peptide (A), 131 (B), or PY/31 (C) peptides at 500 ~g/ml, or 40 mM phenylphosphate (D) were added to the primary antibody solution 
to assess the specificity of the staining. Bar, 20 #m. 
coupled BSA and to the PY~I peptide (Fig. 2, B and C). 
The anti-phosphotyrosine antibodies were also inhibited by 
the PY/~1, peptide (Fig. 2, B and C), again confirming the 
presence of phosphotyrosine on this peptide. 
Detection of 1)~osine-phosphorylated [3~ Subunit in 
RSV-transformed Fibroblasts 
Anti-PY/31  antibodies  immunoprecipitated the  /~,  subunit 
from surface iodinated RSV-transformed mouse NIH3T3 
fibroblasts (Fig.  3,  lane 1),  but not from nontransformed 
cells (Fig.  3,  lane 2).  They also reacted ,,ol0-fold more 
strongly  in  ELISA  experiments  with  lysates  of  RSV- 
transformed cells than with lysates on nontransformed cells 
(Fig.  4  A).  These  results  indicate  that  the  /~1  integrin 
subunit  is  tyrosine-phosphorylated  in  RSV-transformed 
NIH 3T3 fibroblasts, but not, or only at a very low level, 
in normal NIH  3T3  fibroblasts.  Transformation by RSV 
does not affect the overall levels of/31 subunit, as judged by 
immunoprecipitation from lysates of surface iodinated cells 
(not shown) and by ELISA on the cell lysates with anti-31 
(Fig. 4 B). 
Distinct Localization  of 
7~,osine-phosphorylated  {31 lntegrin Subunit in the 
Podosomes of  RSV-transformed Fibroblasts 
We used the new anti-PY/~l antibodies to determine the lo- 
calization of the tyrosine phosphorylated BI subunit in cells 
plated on noncoated glass. In addition to some diffuse stain- 
ing, distinct staining of podosomes was observed in RSV- 
transformed NIH 3T3 fibroblasts (Fig. 5 A). The specificity 
of the anti-PY/31 antibody staining was shown by inhibition 
experiments;  the  PY/~t peptide  specifically inhibited  the 
staining of podosomes as well as the diffuse staining (Fig. 
5  C,  compare  to A),  whereas  the  nonphosphorylated /~, 
peptide (Fig. 5 B) or phenylphosphate (Fig. 5 D) did not 
inhibit. 
In contrast with the specific staining observed in RSV- 
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localization of tyrosine-phos- 
phorylated Bm integrin subunit 
(PYBl),  El  integrin  subunit 
(/31),  and  phosphotyrosine 
(PY) in normal (NIH3T3) and 
RSV-transformed  fRSV-N/H- 
3I'3) fibroblasts plated on non- 
coated glass.  Immunofluores- 
cence was performed with 100 
#g/ml of affinity-purified anti- 
PYB~  antibodies,  10  #g/ml 
affinity-purified  anti-B~  anti- 
bodies, and 10/~g/ml affinity- 
purified anti-phosphotyrosine 
antibodies.  Bar,  20/zm. 
Table L  Immunofluorescent Staining of RSV-transformed and Nontransformed Mouse NIH 3T3 Fibroblasts with 
Anti-tyrosine Phosphorylated {31 Integrin Subunit, Anti-~ Integrin Subunit, Anti-phosphotyrosine,  and 
Anti-p60  ~-s~ Antibodies 
Antibody 
RSV-transformed cells  Nontransformed  cells 
on noncoated  or  RSV-transformed  cells  on noncoated  or  Nontransformed  cells 
vitronectin-coated  on fibronectin-coated  vitronectin-coated  on fibronectin-coated 
substrate  substrate  substrate  substrate 
Anti-tyrosine  Podosomes  Podosomes  Not detected  Not detected 
phosphorylated t3t  diffuse staining  diffuse staining 
subunit 
Anti-~l subunit  Diffuse staining  Adhesion plaques,  Adhesion plaques  Adhesion plaques 
diffuse staining 
Anti-phosphotyrosine  Podosomes,  Podosomes,  Adhesion plaques  Adhesion plaques 
adhesion plaques,  adhesion plaques, 
cell-cell boundaries  cell-cell boundaries 
Anti-p60  "-s~  Podosomes,  Podosomes,  Not detected  Not detected 
adhesion plaques  adhesion plaques 
This table summarizes the data shown in Fig. 6 and Fig. 7 as well as data not shown. Immunofluorescence  microscopy was performed with affinity-purified antibod- 
ies against/31 integrin subunit cytoplasmic peptide (10 #g/mi), PY~t  (100 #g/ml) and phosphotyrosine  (10 #g/ml) or with 10 ~g/ml mouse anti-p60 v'~'~ antibodies 
as described in Materials  and Methods. 
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localization of tyrosine-phos- 
phorylated fll integrin subunit 
(PY/3D,  /51  integrin  subunit 
(/~1)  and  phosphotymsine 
(PY) in normal (NIH3T3) and 
RSV-transformed (RSV-NIH- 
3T3) fibroblasts  plated  on fibro- 
nectin-coated glass. Immuno- 
fluorescence was  performed 
with  100  t~g/ml of affinity- 
purified  anti-PYfl~ antibod- 
ies, 10/~g/ml affinity-purified 
anti-/3~ antibodies and 10/~g/ 
ml affinity-purified  anti-phos- 
photyrosine antibodies.  Bar, 
20/~m. 
transformed fibroblasts (Figs. 5, A, C, and D and Fig. 6 A), 
no anti-PYflt staining above background was obtained in 
nontransformed fibroblasts (Fig. 6 B).  Conventional anti- 
/3t integrin subunit antibodies labeled diffusely RSV-trans- 
formed NIH 3T3 fibroblasts plated on noncoated glass (Fig. 
6 C) and stained adhesion plaques in nontransformed fibro- 
blasts (Fig. 6 D). Anti-phosphotyrosine antibodies stained 
podosomes, adhesion-plaque-like structures (Fig. 6 E) and 
cell-cell boundaries (Table I) in the transformed fibroblasts, 
while adhesion plaques were primarily stained in nontrans- 
formed  fibroblasts  (Fig.  6  F).  Results  indistinguishable 
from those obtained with cells plated on noncoated glass 
(Figs. 5 and 6) were obtained on a vitronectin substrate (Ta- 
ble I). 
In Fig. 7 the staining patterns of anti-PY/3~, anti-/3~ and 
anti-phosphotyrosine  antibodies  were  examined  in  cells 
plated  on  a  fibronectin  substrate.  In  RSV-transformed 
fibroblasts  plated  on  fibronectin  fll  integrin  subunit  im- 
munoreactivity was concentrated in focal adhesions (Fig. 7 
C), while on noncoated glass (Fig. 6 C) and on vitronectin 
(Table I) only diffuse staining was observed. Thus, the anti- 
PY/3t antibody staining is distinct from the localization of 
both ~  subunit and phosphotyrosine immunoreactivities. 
The localization of p60  v-sr~ was also examined for compari- 
son (Table I).  p60  v-'~ was  found both in podosomes and 
in  adhesion  plaques  in  the  RSV-transformed  NIH3T3 
fibroblasts. Control experiments showed that the nonphos- 
phorylated/3, peptide greatly reduces anti-/3, staining and 
phenylphosphate completely inhibits anti-phosphotyrosine 
antibody staining, as does the PY~I peptide (not shown). 
As expected, the nonphosphorylated/3~ peptide had no ef- 
fect on anti-phosphotyrosine staining (not shown). These in- 
hibition  patterns  are  consistent  with  the  ELISA  results 
shown in Fig.  2.  The results with anti-fit, anti-phospho- 
tyrosine and anti-p60  .... antibodies are in agreement with 
results obtained by others using transformed and nontrans- 
formed fibroblasts (Maher et al., 1985; Tarone et al., 1985; 
Chert et al.,  1986;  Giancotti et al.,  1986;  Singer et al., 
1988). 
Even though the anti-PY/3~ antibody staining was not in- 
hibited by phenylphosphate, the PYfl~ epitope does indeed 
encompass a phosphate group, as demonstrated by the ab- 
sence of anti-PYfl, staining of podosomes after treatment of 
the fixed and permeabilized cells with alkaline phosphatase 
(Fig. 8 B, compare with A). Anti-phosphotyrosine staining 
was similarly abolished by the alkaline phosphatase treat- 
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PY/~m and  anti-phosphotyro- 
sine antibody immunofluores- 
cent staining by phosphatase 
treatment.  Immunoltuores- 
cence  was  performed  using 
phosphatase-treated  (B,  D, 
and F) or nontreated (.4, C, 
and E)  fixed and permeabi- 
lized  RSV-translbrmed NIH 
3T3 fibroblasts. The antibod- 
ies used are:  100/~g/ml of af- 
finity-purified  anti-PY~ anti- 
bodies (,4 and B), 10 t~g/ml  of 
afffinity-purified  anti-phospho- 
tyrosine antibodies (C and D) 
and anti-or, integrin antiserum 
at a dilution  of 1:100 (E and F). 
Bar, 20/~m. 
ment (Fig. 8 D, compare to C). Staining of podosomes with 
anti-o~v integrin subunit antibodies confirmed that the podo- 
some structure itself was not destroyed by the phosphatase 
treatment (Fig.  8, E and F). 
Binding of  SH2 Domains to Yjn'osine-phosphorylated 
[3~ lntegrin Subunit Peptide 
Phosphorylated tyrosine residues in proteins often represent 
recognition sites for the SI-I2 domains of cytoplasmic signal- 
ing proteins (Koch et al.,  1991). To examine the possibility 
that tyrosine phosphorylation of the/3~ subunit cytoplasmic 
domain may create a binding site for specific SH2 domains, 
we tested the recombinant SI-I2 domains of several proteins 
in a binding assay. As shown in Fig. 9 A, we found that the 
carboxy-terminal SH2 domain of the p85 subunit of PI-3 ki- 
nase binds to the PY/3~ peptide and, to a lower degree, to 
the related PY/33 peptide. In contrast, the SH2 domains of 
p60  v-src and PLCT-1  did not bind to PYfl~. No binding was 
observed to the/3~ and/33 nonphosphorylated peptides. Fur- 
thermore,  treatment  of  the  PY/3~ peptide  with  alkaline 
phosphatase greatly reduced the binding of the p85  subunit 
SH2 domain (Fig. 9 B). 
Discussion 
We  have  successfully  synthesized a  phosphopeptide  that 
mimics the tyrosine-phosphorylated cytoplasmic domain of 
the  /3~  integrin  subunit,  prepared  antibodies  to  it  that 
specifically recognize the phosphorylated #~  subunit,  and 
shown with these antibodies that tyrosine-phosphorylated 
~  integrins are concentrated in different subcellular struc- 
tures than nonphosphorylated t3~ integrins. Our results also 
show that an SH2 domain of PI-3-kinase binds to the phos- 
phorylated 13~ peptide. 
Our study indicates that polyclonal antibodies specific for 
various  tyrosine-phosphorylated substrates  can  be  useful 
tools, for example, for immunolocalization  studies. Antibod- 
ies specific for the phosphorylated form of a particular pro- 
tein have previously been raised against serine or threonine 
phosphorylated peptides (Czernik et al., 1991). In addition, 
while our manuscript was in preparation, a polyclonal anti- 
body made against a  phosphopeptide comprising a  phos- 
phorylated tyrosine residue of P185  ~eu~erbB-2 was  described 
(Bangalore et al., 1992).  This antibody was also used in im- 
munofluorescence microscopy  experiments;  however,  the 
subcellular localization of the phosphorylated protein was 
not distinct from that of the nonphosphorylated protein or 
from phosphotyrosine in general. 
Our first efforts to produce the PYfl~ phosphopeptide in- 
volved a conventional solid phase synthesis according to an 
FMOC protocol, followed by a  global phosphorylation of 
unblocked  tyrosine  in  the  resin-bound  peptide.  The  3~p 
NMR signal of the deblocked peptide was, however,  later 
shown to have an incorrect chemical shift. We subsequently 
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Figure 9. Binding of SH2 domains to the PYBI and PY~53 peptides. 
The binding assay was performed with 5 #g/ml of the biotinylated 
SH2 domains of the p85 subunit of PI-3-kinase, p60  ~r~ or PLC3, in 
microtiter wells coated with PY/3t,/31, PY/33, or 83 peptides at 10 
#g/ml (A) and with PY/51 or PY/31 dephosphorylated by treatment 
with alkaline phosphatase (B). 
adopted a method employing a benzyl-protected phospho- 
tyrosine in the solid phase synthesis. This method proved to 
be successful when the removal of the FMOC group in each 
step was made with morpholine; attempts to use other bases 
led to loss of  benzyl groups and premature termination of the 
synthesis (Kitas et al.,  1991). 
The antibodies we prepared against the/31  subunit cyto- 
plasmic phosphopeptide recognize the phosphotyrosine resi- 
due in the context of the surrounding/31 subunit amino acid 
sequence. This conclusion is supported by the finding that 
the antibodies did not recognize phosphotyrosine nor other 
tyrosine-phosphorylated peptides,  such as  the  PY/33 pep- 
tide. The antibodies prepared against the PY/3~ subunit pep- 
tide recognized the intact tyrosine-phosphorylated/31 sub- 
unit in  RSV-transformed mouse NIH  3T3  fibroblasts,  as 
shown by ELISA and by surface iodination followed by im- 
munoprecipitation. Phosphate labeling and immunoprecipi- 
tation confirmed that the/31  subunit is phosphorylated in 
RSV-transformed  fibroblasts.  These  experiments  showed 
that  the  anti-PY/3]  antibodies  were  suitable  for  studying 
the  subcellular localization of tyrosine-phosphorylated 13t 
subunit. 
The  overall  distribution  of phosphotyrosine-containing 
proteins had been studied in normal and transformed cells 
(e.g., Maher et al., 1985; Tarone et al., 1985), but the sub- 
cellular distribution of the tyrosine-phosphorylated/31 sub- 
unit was unknown (result not shown). With the anti-PY/3~ 
peptide antibodies, the phosphorylated/31 subunit could be 
detected in RSV-transformed 3T3 fibroblasts without grow- 
ing the cells in the presence of the phosphotyrosine phospha- 
tase inhibitor vanadate. In contrast, significant levels of/31 
subunit phosphorylation could previously be detected after 
imrnunoprecipitation only in cells labeled in the presence of 
vanadate (Hirst et al., 1986; Hynes, 1990; Haimovich et al., 
1991).  Although  the  tyrosine-phosphorylated j3~  subunlt 
represents  only a  minor  fraction of the  total  /31  subunlt 
(Hirst et al.,  1986),  it is concentrated in the podosomes, 
where it is likely to have specific functions. 
Podosomes are dot-shaped sites of close contact with the 
substratum found in some transformed cells and in nontrans- 
formed cells derived from the bone marrow, including os- 
teoclasts (Tarone et al.,  1985;  Marchisio et al.,  1987; see 
Burridge et al.,  1988  for a  review on podosomes).  Podo- 
somes have been reported to contain high levels of cytoskele- 
tal proteins such as actin, ~actinin, fimbrin, vinculin, and 
talin. Pbosphotyrosine containing molecules, some of which 
have been identified as p60  v-s~ substrates, are also concen- 
trated in podosomes (Tarone et al.,  1985;  Kanner et al., 
1991; Wu et al.,  1991). Several characteristics distinguish 
the podosome adhesion structures from adhesion plaques, 
including their rapid assembly and disassembly, which may 
be caused by the low levels of integrins and lack of ECM 
components associated with podosomes,  and may confer 
migratory and invasive properties to cells. The localization 
in podosomes of the tyrosine phosphorylated /31  subunit, 
observed both on vitronectin and fibronectin substrates, is 
distinct from the distribution of the 131  subunit,  which in 
transformed cells is diffusely distributed on a  vitronectin 
substrate or on uncoated glass (Chen et al., 1986; Giancotti 
et al.,  1986;  Ruoslahti and Giancotti, 1989;  Hynes, 1990) 
and concentrated in adhesion plaques on a fibronectin sub- 
strate (Chen et al.,  1986;  and Table  I).  Thus, one conse- 
quence  of #t  subunlt phosphorylation appears  to  be  the 
substratum-independent localization in podosomes. 
The 131  subunit primarily associates with the o~5 and otv 
subunits in the RSV-transformed NIH 3T3 ceils (not shown). 
However,  because  of  the  low  quantity  of  the  tyrosine- 
phosphorylated/31 subunit, we have not been able to iden- 
tify its companion o~ subunit. The or5 subunit localizes dif- 
fusely in the RSV-transformed fibroblasts and accumulates 
in the adhesion plaques of cells attached on fibronectin (not 
shown),  whereas we detected o~ in the podosomes.  This 
suggests that in the podosomes PY/3~ is present in complex 
with e~v. The o~,/3t integrin is a fibronectin receptor (Vogel 
et al.,  1990),  but unlike ots/~t it does not support the as- 
sembly ofa fibronectin matrix (Zhang et al., 1993). Tyrosine- 
phosphorylated oe43t integrin is probably a  weaker fibro- 
nectin receptor, because phosphorylation has been found to 
reduce the fibronectin binding of a chicken integrin complex 
(Horwitz et al., 1986). Local weak fibronectin binding at the 
podosomes may be important for the degradation of fibro- 
nectin that takes place at this site in RSV-transformed cells 
(Chen et al.,  1985;  Mueller and Chen,  1991). 
The  tyrosine-phosphorylated Bt  subunit  isolated  from 
RSV-transformed chicken fibroblasts has a lower ability to 
interact with fibronectin or talin than integrin from normal 
cells (Tapley et al., 1989).  For this reason, #~ subunlt phos- 
phorylation on tyrosine may contribute to  the  abnormal 
phenotype of RSV-transformed cells.  Consistent with this 
possibility, El subunit tyrosine-phosphorylation was not de- 
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a mutant p60  ,-s'c. Cells infected with this mutant virus re- 
tain surface fibronectin and have a relatively  normal mor- 
phology (Horvath et al.,  1990). 
The tyrosine kinase p60  .... , which presumably is respon- 
sible, directly or indirectly,  for integrin phosphorylation, is 
localized  in podosomes as well  as in adhesion plaques in 
RSV-transformed  cells  (Chen  et  al.,  1985;  and  Table  I). 
However,  the  tyrosine-phosphorylated  /3~  subunit  is  de- 
tected in podosomes, but not in adhesion plaques.  It is not 
clear  why  the  /~  subunit in  the  adhesion  plaques  is  not 
phosphorylated by the p60  ~-s~ present there,  since in vitro 
both the/~l  subunit and a synthetic peptide containing  the 
consensus  site  for  /3~  tyrosine  phosphorylation  are  phos- 
phorylated on tyrosine by p60  .....  (Tapley et al.,  1989).  A 
number of explanations are possible: Some factor necessary 
for integrin phosphorylation may be missing in the plaques 
or there may be locally  high phosphotyrosine phosphatase 
activity.  Alternatively,  p60  v-src may phosphorylate/3~  in the 
plaques, but once phosphorylated, the integrin diffuses away 
from the adhesion plaques because of a decreased interaction 
with talin (Tapley et al.,  1989).  Finally, we cannot exclude 
the  possibility  that tyrosine  phosphorylated  /3~  subunit is 
present in adhesion plaques, but not accessible to the anti- 
bodies. However, this explanation is unlikely since the non- 
phosphorylated B~ subunit is detected in adhesion plaques 
with antibodies to its cytoplasmic domain. Furthermore, it 
was recently  shown that a/3~  subunit mutant in which the 
critical  cytoplasmic  domain  tyrosine  residue  had  been 
replaced  by glutamic acid had a decreased  localization  in 
adhesion plaques of 3T3 cells (Reszka et al.,  1992), suggest- 
ing  that  the  plaque  localization  may  be  abolished  by  in- 
troduction of a negative charge, such as that of a phosphate 
group, at this site.  It is also possible that/3t  subunit phos- 
phorylation on tyrosine could convert adhesion plaques into 
podosomes; podosomes are highly dynamic structures that 
assemble and disassemble  rapidly  (Burridge et al.,  1988). 
The function of tyrosine-phosphorylated/3~  subunit in the 
podosomes  is unknown.  As discussed above,  previous re- 
ports suggest that phosphorylation on tyrosine of its cyto- 
plasmic domain impairs the binding of the/3~  subunit to the 
cytoskeletal proteins that normally interact with it, such as 
talin and vinculin. Our results suggest that an SH2 domain 
of the p85 subunit of PI-3-kinase has affinity for the tyrosine 
phosphorylated/3t  integrin subunit. Although the sequences 
of the cytoplasmic  domains of/3t  and/33  integrins  do not 
conform to the canonical consensus sequence recognized by 
the p85 subunit SH2 domains, exceptions have been reported 
(Miura et al.,  1994).  While an in vivo association remains 
to be demonstrated,  it is conceivable that the phosphoryla- 
tion of the #~ integrin subunlt in RSV-transformed cells may 
act to recruit PI-3-kinase to a critical  subcdlular localiza- 
tion.  PI-3-kinase  phosphorylates  several  phosphoinositide 
membrane  lipids  at the  D-3  position of the  inositol  ring. 
Thus, binding to tyrosine-phosphorylated/3~  subunit would 
bring PI-3-kinase in contact not only with its substrates, but 
also with p60  ~-sr~. PI-3-kinase is a substrate of 1360  .... and it 
is likely to be activated by tyrosine phosphorylation of its 85- 
kD  subunit  (Cantley  et  al.,  1991).  Interestingly,  the  in- 
creased concentration of D-3 phosphorylated phosphoinosi- 
tides resulting  from the activation of PI-3-kinase,  may be 
responsible  for  the  disorganization  of actin  filament  ob- 
served in cells treated with growth factors and in transformed 
cells (Cantley et al.,  1991). Further work will be necessary 
to evaluate the intriguing hypothesis that the phosphorylated 
~  subunit in the  podosomes  may,  in analogy  with  phos- 
phorylated growth factor receptors, recruit cytoplasmic sig- 
naling molecules. 
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